Browsing Tag
Breast Cancer
60 posts
Why Celcuity’s FDA priority review for gedatolisib could reset the breast cancer playbook
Celcuity earns FDA priority review for gedatolisib in advanced breast cancer. Find out what the July 2026 PDUFA date means for its market trajectory.
Kazia Therapeutics (NASDAQ: KZIA) unveils immune-boosting effects of paxalisib in advanced breast cancer at SABCS 2025
Find out how Kazia Therapeutics’ paxalisib is breaking new ground in breast cancer immunotherapy. Read the latest clinical insights from SABCS 2025.
Lunit submits FDA filing for AI mammography model: What’s next for U.S. breast cancer screening?
Find out how Lunit’s FDA-bound artificial intelligence risk model could change breast cancer screening and prevention in the United States. Read the full story.
Roche’s breast cancer pill inavolisib approved by MHRA for metastatic disease
MHRA approves inavolisib for advanced HR-positive breast cancer. Find out how Roche’s targeted therapy expands treatment options for UK patients.
Johnson & Johnson grabs RIPTAC cancer tech in $3bn Halda Therapeutics deal
Johnson & Johnson acquires Halda Therapeutics for $3.05B, expanding its oncology portfolio with precision prostate cancer treatments. Find out what’s next.
Clairity raises $43m to scale first FDA-authorized AI platform for breast cancer risk prediction
Find out how Clairity’s FDA-authorized AI platform and $43M Series B funding aim to transform breast cancer risk prediction and preventive care.
How Celcuity Inc.’s gedatolisib trial results sent its stock soaring 46% in a single morning
Celcuity stock surged 46% after Phase 3 trial data showed strong efficacy for gedatolisib in HR+/HER2- breast cancer. Find out what this means for investors.
Can Roche’s 62% success rate in breast cancer trials spark the next oncology breakthrough?
Roche’s new oral breast-cancer therapy cut disease-progression risk by up to 62% in late-stage trials. Find out how it could reshape treatment in 2025.
BCAL Diagnostics (ASX: BDX) shares rise after ClearNote deal — is this the turning point investors were waiting for?
BCAL Diagnostics (ASX: BDX) expands with ClearNote Health deal for ovarian and pancreatic cancer tests—can this pivot revive its struggling stock?
Lilly’s Verzenio hits overall survival milestone in early breast cancer after 2-year treatment
Verzenio improves survival in high-risk early breast cancer, confirms Eli Lilly. Find out how this changes the treatment landscape.